Clinical Trial Update: Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases [Phase 3]

View source ↗

Summary

ClinicalTrials.gov update on a Phase 3 study evaluating rituximab in combination with mycophenolate mofetil for interstitial lung diseases. The trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Lung Disease, Interstitial | Phase 3 | Status: COMPLETED